Discussion about 2 cases of intractable headache from brain tumor in which opioids were effective and a hypothesis regarding the underlying mechanism

Onishi, Keiko; Hosokawa, Toyoshi; Tsubokura, Takuji; Fukazawa, Keita; Ueno, Hiroshi; Kwon, Chul; Harada, Akiho; Fukazawa, Madoka; Yamashiro, Akiko; Taniguchi, Ayano; Hatano, Kiyohiko; Tanaka, Moegi; Nakasone, Arisa; Okada, Megumi

doi:10.2512/jspm.10.509

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We performed these therapies, although concurrent headaches due to GBM recurrence and migraines were experienced. Since nonsteroidal anti-inflammatory medicines are ineffective for treating headache caused by elevated intracranial pressure, hyperosmotic fluids like concentrated glycerin, fructose, or D-mannitol, steroids, and cerebral edema are typically utilized to treat the condition [5]. The management of headaches is important because headaches exacerbate the patient's quality of life.…”

Section: Discussionmentioning

confidence: 99%

Fremanezumab Improved Migraine and Headache Attributed to Glioblastoma

Kawamura¹,

Katsuki²,

Kashiwagi³

et al. 2022

Cureus

View full text Add to dashboard Cite

Fremanezumab, one of the anti-calcitonin gene-related peptide monoclonal antibodies, is widely used for migraine prophylaxis. However, its efficacy for headache attributed to glioblastoma has not been reported. We herein report a 66-year-old man who had right temporoparietal glioblastoma which recurred despite surgical and chemo-radiological treatment. He had migraine and headache attributed to glioblastoma, but fremanezumab improved both of them. Our case suggested that fremanezumab's possible efficacy for not only migraine but also headache attributed to intracranial neoplasia.

show abstract

Section: Discussionmentioning

confidence: 99%

Fremanezumab Improved Migraine and Headache Attributed to Glioblastoma

Kawamura¹,

Katsuki²,

Kashiwagi³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

頭蓋内がん病変による難治性の頭痛および/または悪心に対するミダゾラム持続投与の有用性

Hagiwara,

Makino,

Harada

et al. 2024

Palliat Care Res

View full text Add to dashboard Cite

To investigate the e ectiveness and safety of continuous infusion of midazolam for the treatment of headache and/or nausea/vomiting in patients with brain tumors or cancer-associated meningitis. Methods: Patients who presented with headache and/or nausea/vomiting and underwent continuous infusion of midazolam from April 2005 to March 2021 were retrospectively analyzed. Results: Among 22 patients, 19 presented with headache and 14 with nausea/vomiting. e success rate of continuous infusion of midazolam for headache was 89% and that for nausea/vomiting was 78%. e mean number of vomiting episodes within 24 hours from the start of midazolam administration was 0.14±0.36, which was signi cantly lower than that from 24 hours before to the start of administration (1.43±1.60, P=0.015). Sedation was observed as an adverse event in ve (23%) patients, but no patients developed respiratory depression. Conclusion: When conventional therapies are ine ective for headache and/or nausea/vomiting caused by brain tumors or cancer-associated meningitis, continuous infusion of midazolam may improve symptoms and should be considered as a treatment option.

show abstract

Discussion about 2 cases of intractable headache from brain tumor in which opioids were effective and a hypothesis regarding the underlying mechanism

Cited by 2 publications

References 0 publications

Fremanezumab Improved Migraine and Headache Attributed to Glioblastoma

Fremanezumab Improved Migraine and Headache Attributed to Glioblastoma

頭蓋内がん病変による難治性の頭痛および/または悪心に対するミダゾラム持続投与の有用性

Contact Info

Product

Resources

About